---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-015928"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T19:28:50.316859+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

## Summary
- Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.
- Revenue $10.1M, down 27.3% from $13.9M; operating loss $1.1M vs $0.7M income.
- Nine-month net loss $1.5M ($0.05 loss per share) vs net income $1.0M ($0.03 EPS).
- Two largest customers in Contract Manufacturing segment represented 90% of nine-month revenue (83% prior year).

## SEC filing metadata
- accession: 0001437749-26-015928
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/inbp20260507_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-015928
- JSON: https://secwatch.observer/filing/0001437749-26-015928.json
- Plain text: https://secwatch.observer/filing/0001437749-26-015928.txt

## Source-grounded claims
- claim_id: 099667fbc62a114f1c1a95695bfbcfa62b1d5054
  claim: INTEGRATED BIOPHARMA INC reported nine months ended March 31, 2026 results: revenue $34.1 million, net income net loss of $1.5 million, EPS $(0.05).
  evidence_excerpt: ended March 31, 2026 compared to operating income in the quarter ended March 31, 2025 of approximately $0.7 million. Revenue for the nine-month period ended March 31, 2026 was $34.1 million compared to $40.2 million for the nine-month period ended March 31, 2025, a decrease of $6.1 million or 15.2%. The Company had an operating loss for the nine-month period ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm
- claim_id: f12a2b6e7595b51cc6d9edb2f5f53be62ff81984
  claim: INTEGRATED BIOPHARMA INC reported quarter ended March 31, 2026 results: revenue $10.1 million, net income net loss of $0.8 million, EPS $(0.03).
  evidence_excerpt: BioPharma, Inc. ((OTCQX: INBP)) (the “Company” or “INBP”) reports its financial results for the quarter ended March 31, 2026. Revenue for the quarter ended March 31, 2026 was $10.1 million compared to $13.9 million for the quarter ended March 31, 2025, a decrease of $3.8 million or 27.3%. The Company had an operating loss of $1.1 million in the quarter ended March
  evidence_url: https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.